Media coverage
2
Media coverage
Title -Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes Media name/outlet M2 PressWIRE Country/Territory United Kingdom Date 2/12/22 URL ct.moreover.com/?a=49406084801&p=1gw&v=1&x=ruAgBGa_1iUpolTptxzu6A Persons Mauricio Burotto Title -Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes Media name/outlet ENP Newswire Country/Territory United Kingdom Date 2/12/22 URL ct.moreover.com/?a=49406086092&p=1gw&v=1&x=aBzVuSDrHczfEWMUSJGxOQ Persons Mauricio Burotto